Ethanol transformation into higher hydrocarbons over HZSM-5 zeolite: Direct detection of radical species by in situ EPR spectroscopy

International audienceHZSM-5 (Si/Al ratio = 40) zeolite is an efficient catalyst for ethanol transformation due to its capacity to maintain a high activity in C3 + hydrocarbons formation with time-on-stream (TOS) and this in spite of a great loss of acidity and microporosity and a high coke content deposited inside the pores of the zeolite. A study by in situ Electron Paramagnetic Resonance (EPR) spectroscopy in ethylene conversion to hydrocarbons showed that a fraction of radicals was active

Downscaling with an unstructured coastal-ocean model to the Goro Lagoon and the Po river delta branches

The Goro Lagoon Finite Element Model (GOLFEM) presented in this paper concentrates on the high-resolution downscaled model of the Goro Lagoon, along with five Po river branches and the coastal area of the Po delta in the northern Adriatic Sea (Italy) where crucial socio-economic activities take place. GOLFEM was validated by means of validation scores (bias – BIAS, root mean square error – RMSE, and mean absolute error – MAE) for the water level, current velocity, salinity and temperature measured at several fixed stations in the lagoon. The range of scores at the stations are: for temperature between −0.8 to +1.2◦C, for salinity from −0.2 to 5 PSU, for sea level 0.1 m. The lagoon is dominated by an estuarine vertical circulation due to a double opening at the lagoon mouth and sustained by multiple sources of freshwater inputs. The non-linear interactions among the tidal forcing, the wind and the freshwater inputs affect the lagoon circulation at both seasonal and daily time scales. The sensitivity of the circulation to the forcings was analyzed with several sensitivity experiments done with the exclusion of the tidal forcing and different configurations of the river connections. GOLFEM was designed to resolve the lagoon dynamics at high resolution in order to evaluate the potential effects on the clam farming of two proposed scenarios of human intervention on the morphology of the connection with the sea. We calculated the changes of the lagoon current speed and salinity, and using opportune fitness indexes related to the clams physiology, we quantified analytically the effects of the interventions in terms of extension and persistence of areas of the clams optimal growth. The results demonstrate that the correct management of this kind of fragile environment relies on both long-term (intervention scenarios) and short-term (coastal flooding forecasts and potential anoxic conditions) modeling, based on a flexible tool that is able to consider all the recorded human interventions on the river connections. This study also demonstrates the importance of designing a seamless chain of models that are capable of integrating local effects into the coarser operational oceanographic models

Regeneration of an Aged Hydrodesulfurization Catalyst by Non-Thermal Plasma: Characterization of Refractory Coke Molecules

International audienceThis study describes the phenomena involved during the regeneration of an aged industrial hydrodesulfurization catalyst (CoMoP/Al2O3) using a non-thermal plasma at a low temperature (200 °C). The changes occurring during regeneration were studied by characterizing spent, partially, and fully regenerated catalysts by XRD, Raman, TEM spectroscopy, and the coke deposited on the catalyst surface by Laser desorption/ionization time-of-flight mass spectrometry (LDI TOF/MS). The coke is a mixture of several polycyclic molecules, the heaviest with a coronene backbone, containing up to seven sulfur atoms. This kinetic study shows that the oxidation rate depends on the nature of the coke. Hence, explaining the formation of VOCs from heavy polycyclic carbon molecules without complete oxidation to CO2. However, XRD and Raman spectroscopies evidence CoMoO4 formation after a long treatment time, indicating hot spots during the regeneration

The location of DCX mutations predicts malformation severity in X-linked lissencephaly

International audienceLissencephaly spectrum (LIS) is one of the most severe neuronal migration disorders that ranges from agyria/pachygyria to subcortical band heterotopia. Approximately 80% of patients with the LIS spectrum carry mutations in either the LIS1 or DCX (doublecortin) genes which have an opposite gradient of severity. The aim of the study was to evaluate in detail the phenotype of DCX-associated lissencephaly and to look for genotype-phenotype correlations. Of the 180 male patients with DCX-related lissencephaly, 33 males (24 familial cases and nine cases with de novo mutations) were found with hemizygous DCX mutations and were clinically and genetically assessed here. DCX mutation analysis revealed that the majority of mutations were missense (79.2%), clustered in the two evolutionary conserved domains, N-DC and C-DC, of DCX. The most prominent radiological phenotype was an anteriorly predominant pachygyria or agyria (54.5%) although DCX-associated lissencephaly encompasses a complete range of LIS grades. The severity of neurological impairment was in accordance with the degree of agyria with severe cognitive impairment in all patients, inability to walk independently in over half and refractory epilepsy in more than a third. For genotype-phenotype correlations, patients were divided in two groups according to the location of DCX missense mutations. Patients with mutations in the C-DC domain tended to have a less severe lissencephaly (grade 4-5 in 58.3%) compared with those in the N-DC domain (grade 4-5 in 36.3%) although, in this dataset, this was not statistically significant (p=0.12). Our evaluation suggests a putative correlation between phenotype and genotype. These data provide further clues to deepen our understanding of the function of the DCX protein and may give new insights into the molecular mechanisms that could influence the consequence of the mutation in the N-DC versus the C-DC domain of DCX

LIS1-Related Isolated Lissencephaly: Spectrum of Mutations and Relationships With Malformation Severity

International audienceObjective: With the largest data set of patients with LIS1-related lissencephaly, the major cause of posteriorly predominant lissencephaly related to either LIS1 mutation or intragenic deletion, described so far, we aimed to refine the spectrum of neurological and radiological features and to assess relationships with the genotype.Design: Retrospective study.Subjects: A total of 63 patients with posteriorly predominant lissencephaly.Interventions: Of the 63 patients, 40 were found to carry either LIS1 point mutations (77.5%) or small genomic deletions (20%), and 1 carried a somatic nonsense mutation. On the basis of the severity of neuromotor impairment, epilepsy, and radiological findings, correlations with the location and type of mutation were examined.Results: Most patients with LIS1 mutations demonstrated posterior agyria (grade 3a, 55.3%) with thin corpus callosum (50%) and prominent perivascular spaces (67.4%). By contrast, patients without LIS1 mutations tended to have less severe lissencephaly (grade 4a, 41.6%) and no additional brain abnormalities. The degree of neuromotor impairment was in accordance with the severity of lissencephaly, with a high incidence of tetraplegia (61.1%). Conversely, the severity of epilepsy was not determined with the same reliability because 82.9% had early onset of seizures and 48.7% had seizures more often than daily. In addition, neither the mutation type nor the location of the mutation were found to predict the severity of LIS1-related lissencephaly.Conclusion: Our results confirm the homogeneity profile of patients with LIS1-related lissencephaly who demonstrate in a large proportion Dobyns lissencephaly grade 3a, and the absence of correlation with LIS1 mutations

New insights into genotype-phenotype correlations for the doublecortin-related lissencephaly spectrum

X-linked isolated lissencephaly sequence and subcortical band heterotopia are allelic human disorders associated with mutations of doublecortin (DCX), giving both familial and sporadic forms. DCX encodes a microtubule-associated protein involved in neuronal migration during brain development. Structural data show that mutations can fall either in surface residues, likely to impair partner interactions, or in buried residues, likely to impair protein stability. Despite the progress in understanding the molecular basis of these disorders, the prognosis value of the location and impact of individual DCX mutations has largely remained unclear. To clarify this point, we investigated a cohort of 180 patients who were referred with the agyria–pachygyria subcortical band heterotopia spectrum. DCX mutations were identified in 136 individuals. Analysis of the parents’ DNA revealed the de novo occurrence of DCX mutations in 76 cases [62 of 70 females screened (88.5%) and 14 of 60 males screened (23%)], whereas in the remaining cases, mutations were inherited from asymptomatic (n = 14) or symptomatic mothers (n = 11). This represents 100% of families screened. Female patients with DCX mutation demonstrated three degrees of clinical–radiological severity: a severe form with a thick band (n = 54), a milder form (n = 24) with either an anterior thin or an intermediate thickness band and asymptomatic carrier females (n = 14) with normal magnetic resonance imaging results. A higher proportion of nonsense and frameshift mutations were identified in patients with de novo mutations. An analysis of predicted effects of missense mutations showed that those destabilizing the structure of the protein were often associated with more severe phenotypes. We identified several severe- and mild-effect mutations affecting surface residues and observed that the substituted amino acid is also critical in determining severity. Recurrent mutations representing 34.5% of all DCX mutations often lead to similar phenotypes, for example, either severe in sporadic subcortical band heterotopia owing to Arg186 mutations or milder in familial cases owing to Arg196 mutations. Taken as a whole, these observations demonstrate that DCX-related disorders are clinically heterogeneous, with severe sporadic and milder familial subcortical band heterotopia, each associated with specific DCX mutations. There is a clear influence of the individual mutated residue and the substituted amino acid in determining phenotype severity

Phenotypic spectrum and prevalence of INPP5E mutations in Joubert Syndrome and related disorders

<p>Joubert syndrome and related disorders (JSRD) are clinically and genetically heterogeneous ciliopathies sharing a peculiar midbrain-hindbrain malformation known as the 'molar tooth sign'. To date, 19 causative genes have been identified, all coding for proteins of the primary cilium. There is clinical and genetic overlap with other ciliopathies, in particular with Meckel syndrome (MKS), that is allelic to JSRD at nine distinct loci. We previously identified the INPP5E gene as causative of JSRD in seven families linked to the JBTS1 locus, yet the phenotypic spectrum and prevalence of INPP5E mutations in JSRD and MKS remain largely unknown. To address this issue, we performed INPP5E mutation analysis in 483 probands, including 408 JSRD patients representative of all clinical subgroups and 75 MKS fetuses. We identified 12 different mutations in 17 probands from 11 JSRD families, with an overall 2.7% mutation frequency among JSRD. The most common clinical presentation among mutated families (7/11, 64%) was Joubert syndrome with ocular involvement (either progressive retinopathy and/or colobomas), while the remaining cases had pure JS. Kidney, liver and skeletal involvement were not observed. None of the MKS fetuses carried INPP5E mutations, indicating that the two ciliopathies are not allelic at this locus.</p>

Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

Background Anastomotic leak affects 8 per cent of patients after right colectomy with a 10-fold increased risk of postoperative death. The EAGLE study aimed to develop and test whether an international, standardized quality improvement intervention could reduce anastomotic leaks. Methods The internationally intended protocol, iteratively co-developed by a multistage Delphi process, comprised an online educational module introducing risk stratification, an intraoperative checklist, and harmonized surgical techniques. Clusters (hospital teams) were randomized to one of three arms with varied sequences of intervention/data collection by a derived stepped-wedge batch design (at least 18 hospital teams per batch). Patients were blinded to the study allocation. Low- and middle-income country enrolment was encouraged. The primary outcome (assessed by intention to treat) was anastomotic leak rate, and subgroup analyses by module completion (at least 80 per cent of surgeons, high engagement; less than 50 per cent, low engagement) were preplanned. Results A total 355 hospital teams registered, with 332 from 64 countries (39.2 per cent low and middle income) included in the final analysis. The online modules were completed by half of the surgeons (2143 of 4411). The primary analysis included 3039 of the 3268 patients recruited (206 patients had no anastomosis and 23 were lost to follow-up), with anastomotic leaks arising before and after the intervention in 10.1 and 9.6 per cent respectively (adjusted OR 0.87, 95 per cent c.i. 0.59 to 1.30; P = 0.498). The proportion of surgeons completing the educational modules was an influence: the leak rate decreased from 12.2 per cent (61 of 500) before intervention to 5.1 per cent (24 of 473) after intervention in high-engagement centres (adjusted OR 0.36, 0.20 to 0.64; P &lt; 0.001), but this was not observed in low-engagement hospitals (8.3 per cent (59 of 714) and 13.8 per cent (61 of 443) respectively; adjusted OR 2.09, 1.31 to 3.31). Conclusion Completion of globally available digital training by engaged teams can alter anastomotic leak rates. Registration number: NCT04270721 (http://www.clinicaltrials.gov)